Cue Biopharma, Inc. (CUE) Reports Q1 Loss, Misses Revenue Estimates
- Cue Biopharma, Inc. (CUE) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to loss of $0.25 per share a year ago.
- 05/12/2025
|
Cue Biopharma Reports First Quarter 2025 Financial Results and Recent Business Highlights
- Announced Boehringer Ingelheim strategic collaboration and license agreement for CUE-501, including an upfront payment of $12 million and ~$345 million in potential milestone payments
- 05/12/2025
|
Cue Biopharma to Participate in Fireside Chat at the Citizens Life Sciences Conference
- BOSTON, May 05, 2025 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of autoimmune disease and cancer, today announced that it will participate in a fireside chat at the Citizens Life Sciences Conference being held in New York, May 7-8, 2025.
- 05/05/2025
|
Will Cue Biopharma, Inc. (CUE) Report Negative Q1 Earnings? What You Should Know
- Cue Biopharma (CUE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 05/01/2025
|
Cue Biopharma, Inc. (CUE) Business Update Call (Transcript)
- Cue Biopharma, Inc. (NASDAQ:CUE ) Business Update Call April 15, 2025 4:30 PM ET Company Participants Eric Ribner - LifeSci Advisors Dan Passeri - Chief Executive Officer Lucinda Warren - Chief Business Officer Operator Good day, and welcome to the Cue Biopharma Business Update Call. All participants are in a listen-only mode.
- 04/15/2025
|
Boehringer Ingelheim and Cue Biopharma partner to develop next-generation treatment for autoimmune and inflammatory diseases
- Ingelheim, Germany, and Boston, MA, USA, April 14, 2025 – Boehringer Ingelheim and Cue Biopharma, Inc. (Nasdaq: CUE) today announced a strategic research collaboration and license agreement to develop and commercialize Cue Biopharma's CUE-501 product candidate, a differentiated B cell depletion therapy for autoimmune diseases. Cue Biopharma is a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the potential treatment of autoimmune and inflammatory diseases.
- 04/15/2025
|
Cue Biopharma Announces Pricing of Approximately $20 Million Public Offering
- BOSTON, April 14, 2025 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of cancer and autoimmune disease, today announced the pricing of an underwritten public offering of (i) 13,530,780 shares of its common stock and accompanying common stock warrants to purchase an aggregate of 3,382,695 shares of common stock and, (ii) to certain investors in lieu of common stock, pre-funded warrants to purchase 11,469,216 shares of common stock and accompanying common stock warrants to purchase an aggregate of 2,867,304 shares of common stock. Each share of common stock and accompanying common stock warrant are being sold together at a combined public offering price of $0.79, and each pre-funded warrant and accompanying common stock warrant are being sold together at a combined public offering price of $0.789. The aggregate gross proceeds of the offering are expected to be approximately $20 million, before deducting underwriting discounts and commissions and other offering expenses. Each pre-funded warrant will have an exercise price of $0.001 per share, will be exercisable immediately and will be exercisable until all of the pre-funded warrants are exercised in full. Each common stock warrant will have an exercise price of $0.79 per share, will be exercisable immediately and will expire five years from the date of issuance. The offering is expected to close on or about April 16, 2025, subject to satisfaction of customary closing conditions. All of the securities are being offered by Cue Biopharma.
- 04/14/2025
|
Cue Biopharma Announces Proposed Public Offering
- BOSTON, April 14, 2025 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of cancer and autoimmune disease, today announced that it is commencing an underwritten public offering of shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) and accompanying warrants to purchase shares of common stock. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering. All of the securities are being offered by Cue Biopharma.
- 04/14/2025
|
Cue Biopharma to Host Business Update Call and Webcast
- BOSTON, April 14, 2025 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of cancer and autoimmune disease, today announced that it will host a conference call and webcast to provide a business update on Tuesday, April 15, 2025 at 4:30 p.m. ET.
- 04/14/2025
|
Boehringer Ingelheim and Cue Biopharma partner to develop next-generation treatment for autoimmune and inflammatory diseases
- INGELHEIM, Germany and BOSTON, April 14, 2025 (GLOBE NEWSWIRE) -- Boehringer Ingelheim and Cue Biopharma, Inc. (Nasdaq: CUE) today announced a strategic research collaboration and license agreement to develop and commercialize Cue Biopharma's CUE-501 product candidate, a differentiated B cell depletion therapy for autoimmune diseases. Cue Biopharma is a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the potential treatment of autoimmune and inflammatory diseases.
- 04/14/2025
|
Cue Biopharma, Inc. (CUE) Reports Q4 Loss, Misses Revenue Estimates
- Cue Biopharma, Inc. (CUE) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.16. This compares to loss of $0.28 per share a year ago.
- 03/31/2025
|
Cue Biopharma Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights
- BOSTON, March 31, 2025 (GLOBE NEWSWIRE) -- - Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of cancer and autoimmune disease, today reported fourth quarter and full year 2024 financial results.
- 03/31/2025
|
Cue Biopharma Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- BOSTON, Mass., Nov. 29, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of cancer and autoimmune disease, today announced the grant of an inducement option award to its newly appointed interim chief development officer, Daniel Baker, M.D. The grant was approved by a majority of the independent directors of the Company as inducement material to Dr. Baker entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4) (“the Inducement Award”).
- 11/29/2024
|
Cue Biopharma to Participate in Fireside Discussion at the Piper Sandler 36th Annual Healthcare Conference
- BOSTON, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of cancer and autoimmune disease, announced today that it will take part in an unplugged fireside discussion at the Piper Sandler 36th Annual Healthcare Conference being held in New York, NY, Dec 3-5, 2024.
- 11/25/2024
|
Cue Biopharma, Inc. (CUE) Reports Q3 Loss, Tops Revenue Estimates
- Cue Biopharma, Inc. (CUE) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.20. This compares to loss of $0.24 per share a year ago.
- 11/14/2024
|
Cue Biopharma Reports Third Quarter 2024 Financial Results and Recent Business Highlights
- BOSTON, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of cancer and autoimmune disease, today provided a business and financial update for the third quarter of 2024.
- 11/14/2024
|
Cue Biopharma Announces Strategic Organizational Transition
- BOSTON, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of cancer and autoimmune disease, today announced that Daniel Baker, M.D., will join Cue Biopharma as interim chief development officer (CDO) effective November 25, 2024. Dr. Anish Suri will transition from his current role of president & chief scientific officer (CSO) and will serve the company as principal research and immunology advisor effective as of the same date.
- 11/14/2024
|
Cue Biopharma Presents Positive Updated Data from its Phase 1 Trials of CUE-101 and CUE-102 in Head and Neck Cancer and WT1 Positive Cancers at the SITC 39th Annual Meeting
- BOSTON, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of cancer and autoimmune disease, today presented updated data from its Phase 1 dose escalation and expansion trial evaluating its lead oncology asset from the Immuno-STAT™ CUE-100 series, CUE-101, in patients with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). The data was presented in an oral session at the Society for Immunotherapy of Cancer's 39th Annual Meeting (SITC 2024) being held in Houston, Texas and virtually November 6-10.
- 11/08/2024
|
Cue Biopharma Announces Upcoming Scientific Presentations at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting
- BOSTON, Oct. 04, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells, today announced it will deliver an oral and a poster presentation on the company's Immuno-STAT™ clinical assets CUE-101 and CUE-102, representative of the CUE-100 series, at the Society for Immunotherapy of Cancer's 39th Annual Meeting (SITC 2024). The conference will be held in Houston, Texas, on November 6-10, 2024.
- 10/04/2024
|
Cue Biopharma Announces Pricing of $12.0 Million Public Offering
- BOSTON, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells, today announced the pricing of an underwritten public offering of (i) 11,564,401 shares of its common stock and accompanying common stock warrants to purchase an aggregate of 2,891,100 shares of common stock and, (ii) to certain investors in lieu of common stock, pre-funded warrants to purchase 12,435,599 shares of common stock and accompanying common stock warrants to purchase an aggregate of 3,108,900 shares of common stock. Each share of common stock and accompanying common stock warrant are being sold together at a combined public offering price of $0.50, and each pre-funded warrant and accompanying common stock warrant are being sold together at a combined public offering price of $0.499. The aggregate gross proceeds of the offering are expected to be approximately $12.0 million, before deducting underwriting discounts and commissions and other offering expenses. Each pre-funded warrant will have an exercise price of $0.001 per share, will be exercisable immediately and will be exercisable until all of the pre-funded warrants are exercised in full. Each common stock warrant will have an exercise price of $0.50 per share, will be exercisable immediately and will expire five years from the date of issuance. The offering is expected to close on or about September 30, 2024, subject to satisfaction of customary closing conditions. All of the securities are being offered by Cue Biopharma.
- 09/26/2024
|
Cue Biopharma Announces Proposed Public Offering
- BOSTON, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells, today announced that it is commencing an underwritten public offering of shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) and accompanying warrants to purchase shares of common stock. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering. All of the securities are being offered by Cue Biopharma.
- 09/26/2024
|
Cue Biopharma Announces Proposed Public Offering
- BOSTON, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells, today announced that it is commencing an underwritten public offering of shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) and accompanying warrants to purchase shares of common stock. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering. All of the securities are being offered by Cue Biopharma.
- 09/26/2024
|
Cue Biopharma Appoints Industry Veteran Lucinda Warren as Chief Business Officer
- BOSTON, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells, today announced the appointment of industry veteran Lucinda Warren as chief business officer (CBO).
- 09/09/2024
|
Cue Biopharma, Inc. (CUE) Q2 2024 Earnings Call Transcript
- Cue Biopharma, Inc. (NASDAQ:CUE ) Q2 2024 Earnings Conference Call August 19, 2024 4:30 PM ET Company Participants Daniel Passeri - CEO Anish Suri - President & Chief Scientific Officer Matteo Levisetti - Chief Medical Officer Conference Call Participants Stephen Willey - Stifel Ren Benjamin - Citizens JMP Maury Raycroft - Jefferies Leland Gershell - Oppenheimer Edward Tenthoff - Piper Sandler Operator Good day, and welcome to the Cue Biopharma Second Quarter 2024 Earnings Call. All participants will be in a listen-only mode.
- 08/19/2024
|
Cue Biopharma Reports Second Quarter 2024 Financial Results and Recent Business Highlights
- BOSTON, Aug. 19, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells, provided a business and financial update for the second quarter 2024.
- 08/19/2024
|
Cue Biopharma, Inc. (CUE) Reports Q2 Loss, Tops Revenue Estimates
- Cue Biopharma, Inc. (CUE) came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of a loss of $0.29. This compares to loss of $0.29 per share a year ago.
- 08/14/2024
|
Medical Moonshots: 3 Biotech Stocks Set to Skyrocket
- Human life expectancy has doubled since the 1900s, mostly attributed to advancements in lifestyle, living standards and medicine. Thanks to biotech companies that produce transformative drugs and treatments, we now have the collective ability to combat diseases that used to bring entire nations down.
- 05/30/2024
|
Cue Biopharma to Present at the 20th Annual PEGS Boston Summit
- BOSTON, May 08, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate disease-specific T cells, announced today that it will deliver two poster presentations at the 20th PEGS Boston Summit, the Essential Protein and Antibody Engineering Summit, being held May 13-17, 2024 in Boston, MA and virtually.
- 05/08/2024
|
Here's Why Cue Biopharma (CUE) is Poised for a Turnaround After Losing -22.83% in 4 Weeks
- Cue Biopharma (CUE) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
- 04/25/2024
|
Cue Biopharma to Present at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
- BOSTON, April 24, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate disease-specific T cells, announced today that it will present an oral abstract and poster at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 31 – June 4, 2024 in Chicago, IL.
- 04/24/2024
|
Here's Why Cue Biopharma (CUE) Is a Great 'Buy the Bottom' Stock Now
- Cue Biopharma (CUE) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
- 04/15/2024
|
Cue Biopharma, Inc. (CUE) Q4 2023 Earnings Call Transcript
- Cue Biopharma, Inc. (NASDAQ:CUE ) Q4 2023 Earnings Conference Call April 8, 2024 4:30 PM ET Company Participants Daniel Passeri - CEO Matteo Levisetti - Chief Medical Officer Anish Suri - President & Chief Scientific Officer Kerri-Ann Millar - CFO Conference Call Participants Stephen Willey - Stifel Ren Benjamin - JMP Operator Greetings and welcome to the Cue Biopharma Investor Update call. At this time, all participants are in listen-only mode.
- 04/08/2024
|
Cue Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results and Updated Business Highlights
- BOSTON, April 08, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate disease-specific T cells, today reported fourth quarter and full year 2023 financial results.
- 04/08/2024
|
Cue Biopharma's Lead Clinical Asset, CUE-101, to be Featured at the 2024 Multi-disciplinary Head and Neck Cancers Symposium
- BOSTON, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate disease-specific T cells, announced today that the company's lead clinical asset, CUE-101, will be featured in a presentation at the 2024 Multi-disciplinary Head and Neck Cancers Symposium given by Alexander Dimitrios Colevas, M.D., a principal investigator at Stanford University participating in the CUE-101 clinical trial. The symposium is being held in Phoenix, Arizona and virtually from February 29 – March 2, 2024.
- 02/29/2024
|
Cue Biopharma to Present at the JMP Securities Hematology and Oncology Summit
- BOSTON, Nov. 22, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of T cell engagers to selectively modulate tumor-specific T cells, announced today that it will take part in a fireside chat at the JMP Securities Hematology and Oncology Summit being held virtually from December 5-6, 2023.
- 11/22/2023
|
Cue Biopharma, Inc. (CUE) Q3 2023 Earnings Call Transcript
- Cue Biopharma, Inc. (NASDAQ:CUE ) Q3 2023 Earnings Conference Call November 9, 2023 4:30 PM ET Company Participants Daniel Passeri - CEO Matteo Levisetti - Chief Medical Officer Anish Suri - President & Chief Scientific Officer Kerri-Ann Millar - CFO Conference Call Participants Reni Benjamin - JMP Securities Ted Tenthoff - Piper Sandler Operator Good afternoon, ladies and gentlemen, and welcome to the Cue Biopharma Third Quarter 2023 Earnings Call. At this time, all lines are in listen-only mode.
- 11/11/2023
|
Cue Biopharma to Present at Three Upcoming Investor Healthcare Conferences in November
- BOSTON, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of T cell engagers to selectively modulate tumor-specific T cells, announced today that it will participate in three investor conferences this November, the Stifel Healthcare Conference, to be held in New York from November 14-15, the Jefferies London Healthcare Conference, to be held in London from November 14-16, and the Piper Sandler Annual Healthcare Conference, to be held in New York from November 28-30.
- 11/07/2023
|
Cue Biopharma Presents New Positive Data from Phase 1 Trials of CUE-101 in Head and Neck Cancer and CUE-102 in Wilms' Tumor 1 Positive Cancers at SITC 2023
- BOSTON, Nov. 03, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of T cell engagers to selectively modulate tumor-specific T cells, announced today the presentation of new positive data from its ongoing fully enrolled Phase 1 trials evaluating its lead interleukin-2 (IL-2)-based T cell engager, CUE-101, as a monotherapy and in combination with KEYTRUDA® (pembrolizumab) for patients with recurrent/metastatic HPV+ head and neck squamous cell carcinoma (HNSCC). New clinical data will also be reported from the company's ongoing Phase 1 trial evaluating its second candidate, CUE-102, for the treatment of Wilms' Tumor 1 positive (WT1+) recurrent/metastatic cancers.
- 11/03/2023
|
Cue Biopharma Announces Upcoming Scientific Presentations at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting
- BOSTON, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient's body, announced today two poster presentations highlighting the company's Immuno-STAT™ platform and lead clinical assets CUE-101 and CUE-102, representative of the CUE-100 series, at the Society for Immunotherapy of Cancer's 38th Anniversary Annual Meeting (SITC 2023). The conference will be held in San Diego, California and virtually on November 1-5, 2023.
- 09/27/2023
|
Cue Biopharma Announces Completion of Patient Enrollment in Phase 1b Study of CUE-101 in Combination with KEYTRUDA®
- BOSTON, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient's body, today announced that it has completed patient enrollment in its Phase 1 clinical trial (NCT03978689) evaluating CUE-101, the company's lead interleukin 2 (IL-2)-based biologic from the CUE-100 series, in combination with KEYTRUDA® (pembrolizumab) as first-line treatment for patients with human papilloma virus positive recurrent/metastatic head and neck squamous cell carcinoma (HPV+ R/M HNSCC).
- 09/26/2023
|
Cue Biopharma, Inc. (CUE) Q2 2023 Earnings Call Transcript
- Cue Biopharma, Inc. (NASDAQ:CUE ) Q2 2023 Earnings Conference Call August 9, 2023 4:30 PM ET Company Participants Dan Passeri - Chief Executive Officer Anish Suri - President & Chief Scientific Officer Matteo Levisetti - Chief Medical Officer Kerri Millar - Chief Financial Officer Conference Call Participants Ted Tenthoff - Piper Sandler Ren Benjamin - JMP Securities Operator Greetings, and welcome to the Cue Biopharma Investor Update Call. At this time, all participants are in a listen-only mode.
- 08/09/2023
|
Cue Biopharma Reports Second Quarter 2023 Financial Results and Recent Business Highlights
- BOSTON, Aug. 09, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient's body, provided a business and financial update for the second quarter 2023.
- 08/09/2023
|
3 Biotech Stocks to Buy as Companies Ink Major Deals
- With patent expirations around the corner, some of the biggest pharmaceutical and biotech companies will soon face generic competition, creating a big opportunity for these top biotech stocks to buy. In 2023 alone, pharmaceutical and biotech companies spent about $85 billion on acquisitions.
- 06/22/2023
|
Cue Biopharma to Present at the Jefferies 2023 Global Healthcare Conference
- BOSTON, June 05, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient's body, announced today that it will present at the Jefferies Global Healthcare Conference being held June 7–9, 2023 in New York.
- 06/05/2023
|
3 Biotech Stocks Sitting on Huge-Upside Catalysts
- Now is a great time to start accumulating top biotech stocks. The biotech boom is red-hot.
- 05/26/2023
|
Cue Biopharma to Present at the Upcoming JMP Securities Life Sciences Conference
- BOSTON, May 08, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient's body, announced today that it will take part in a fireside chat at the JMP Securities Life Sciences Conference being held at the New York Hilton Midtown, May 15-16, 2023.
- 05/08/2023
|
7 High-Potential Penny Stocks in the Biotech Sector
- Most of the biggest biotech stocks on the market started off as unknown penny stocks. Look at Axsome Therapeutics (NASDAQ: AXSM ), for example.
- 05/04/2023
|
Cue Biopharma, Inc. (CUE) Q4 2022 Earnings Call Transcript
- Cue Biopharma, Inc. (NASDAQ:CUE ) Q4 2022 Earnings Conference Call March 21, 2023 4:30 PM ET Company Participants Dan Passeri - CEO Matteo Levisetti - Chief Medical Officer Ken Pienta - Clinical Advisory Anish Suri - President and Chief Scientific Officer Kerri Millar - CFO Sara Pai - Surgical Oncologist and Director, Translational Head and Neck Cancer Research, Mass General Hospital Conference Call Participants Ted Tenthoff - Piper Sandler Ren Benjamin - JMP Securities Mark Breidenbach - Oppenheimer Stephen Willey - Stifel Operator Greetings, and welcome to the Cue Biopharma Fourth Quarter and Full Year 2022 Earnings Call. [Operator Instructions] As a reminder, this conference is being recorded.
- 03/21/2023
|
Cue Biopharma to Host Business Update Call and Webcast
- BOSTON, March 15, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient's body, announced today that it will host a conference call and webcast to provide a business and clinical update on Tuesday, March 21, 2023 at 4:30 p.m. EDT. Live and archived versions of the event can be accessed via the Company's website.
- 03/15/2023
|
Cue Biopharma to Present at Two February 2023 Scientific Conferences
- BOSTON, Feb. 01, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient's body, announced today that its President and Chief Scientific Officer, Anish Suri, Ph.D., will participate in two scientific conferences this February, the Immuno-Oncology 360 o Summit, taking place February 7-10 in New York, NY, and the Federation of American Societies for Experimental Biology (FASEB) Catalyst Conference, taking place virtually February 8-9, 2023.
- 02/01/2023
|
Cue Biopharma, Inc. (CUE) Q3 2022 Earnings Call Transcript
- Cue Biopharma, Inc. (NASDAQ:CUE ) Q3 2022 Earnings Conference Call November 14, 2022 4:30 PM ET Company Participants Dan Passeri - Chief Executive Officer Anish Suri - President & Chief Scientific Officer Ken Pienta - Acting Chief Medical Officer Matteo Levisetti - Senior Vice President of Clinical Development Kerri Millar - Chief Financial Officer Conference Call Participants Reni Benjamin - JMP Securities Operator Greetings, and welcome to the Cue Biopharma Update Call. A question-and-answer session will follow the presentation.
- 11/14/2022
|
Cue Biopharma to Present at Two Upcoming Investor Healthcare Conferences in November
- BOSTON, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate tumor-specific T cells directly within the patient's body, announced today that it will present at two investor conferences this November, the Stifel Healthcare Conference 2022, to be held November 15-16 in New York, and the Jefferies London Healthcare Conference, to be held in London, UK, November 15-17.
- 11/09/2022
|
Cue Biopharma to Host Business Update Call and Webcast
- BOSTON, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate tumor-specific T cells directly within the patient's body, announced today that it will host a conference call and webcast to provide a business update on Monday, November 14, 2022 at 4:30 p.m. EST. Live and archived versions of the event can be accessed via the Company's website.
- 11/07/2022
|
Cue Biopharma, Inc. (CUE) CEO Dan Passeri on Q2 2022 Results - Earnings Call Transcript
- Cue Biopharma, Inc. (NASDAQ:CUE ) Q2 2022 Earnings Conference Call August 23, 2022 4:30 PM ET Company Participants Dan Passeri - Chief Executive Officer Anish Suri - President & Chief Scientific Officer Ken Pienta - Acting Chief Medical Officer Matteo Levisetti - SVP, Clinical Development Kerri Millar - Chief Financial Officer Conference Call Participants Stephen Wiley - Stifel Reni Benjamin - JMP Securities Mark Breidenbach - Oppenheimer Operator Greetings and welcome to the Cue Biopharma Update Call. At this time, all participants are in a listen-only mode.
- 08/23/2022
|
Here's Why Cue Biopharma, Inc. (CUE) Looks Ripe for Bottom Fishing
- Cue Biopharma, Inc. (CUE) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
- 08/23/2022
|
Cue Biopharma to Present at the Guggenheim I&I Spotlight Series
- BOSTON, July 11, 2022 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate tumor-specific T cells directly within the patient's body, announced today that it will take part in a fireside chat at the Guggenheim I&I Spotlight Series – Treg-based Therapies being held July 12–13, 2022.
- 07/11/2022
|
Cue Biopharma to Present at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
- BOSTON, May 26, 2022 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate targeted T cells directly within the patient's body, announced today it will give a poster presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting to be held in-person June 3–7 at the McCormick Place Convention Center in Chicago, Illinois and virtually.
- 05/26/2022
|
Strength Seen in Cue Biopharma, Inc. (CUE): Can Its 6.4% Jump Turn into More Strength?
- Cue Biopharma, Inc. (CUE) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
- 04/04/2022
|
Cue Biopharma, Inc. (CUE) Stock Jumps 6.5%: Will It Continue to Soar?
- Cue Biopharma, Inc. (CUE) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
- 02/15/2022
|
Cue Biopharma, Inc. (CUE) Soars 8.3%: Is Further Upside Left in the Stock?
- Cue Biopharma, Inc. (CUE) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
- 01/27/2022
|
Cue Biopharma to Host Business Update Call and Webcast for Ongoing CUE-101 Clinical Trials
- CAMBRIDGE, Mass., Jan. 20, 2022 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells directly within the patient's body, announced today it will host a conference call and webcast to provide a clinical update on Wednesday, January 26, 2022 at 4:30 p.m. EST. Live and archived versions of the event can be accessed via the Company's website.
- 01/20/2022
|
Cue Biopharma to Present at the Piper Sandler 33rd Annual Healthcare Conference
- CAMBRIDGE, Mass., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells within the patient's body, announced today that it participated in a pre-recorded fireside chat as part of the Piper Sandler 33rd Annual Virtual Healthcare Conference, being held on November 29-December 2, 2021.
- 11/22/2021
|
Cue Biopharma to Present at Two Upcoming Investor Healthcare Conferences in November
- CAMBRIDGE, Mass., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells directly within the patient's body, announced today that it will take part in two fireside chats, the first at the Stifel Healthcare Conference 2021, November 15-17, and the second at the Jefferies London Healthcare Conference, November 16-19. Both conferences will be held virtually.
- 11/10/2021
|
Analysts Estimate Cue Biopharma, Inc. (CUE) to Report a Decline in Earnings: What to Look Out for
- Cue Biopharma, Inc. (CUE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 11/09/2021
|
Cue Biopharma Granted U.S. Patents on Lead Clinical Program Novel Drug Product Candidate CUE-101
- Patents Further Strengthen and Enhance Intellectual Property (IP) Portfolio Patents Further Strengthen and Enhance Intellectual Property (IP) Portfolio
- 09/21/2021
|
Cue Biopharma, Inc. (CUE) CEO Dan Passeri on Q2 2021 Results - Earnings Call Transcript
- Cue Biopharma, Inc. (CUE) CEO Dan Passeri on Q2 2021 Results - Earnings Call Transcript
- 08/17/2021
|
Cue Biopharma Reports Second Quarter 2021 Results, Recent Data Updates of CUE-101 Phase 1 Dose Escalation and Expansion Study, Platform Progress and Business Highlights
- CAMBRIDGE, Mass., Aug. 17, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the patient's body, provided a business and clinical progress update for the second quarter 2021.
- 08/17/2021
|
Cue Biopharma to Host Business Update Call and Webcast
- CAMBRIDGE, Mass., Aug. 10, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells directly within the patient's body, announced today it will host a conference call and webcast to provide a business update on Tuesday, August 17, 2021 at 4:30 p.m. EDT. Live and archived versions of the event can be accessed via the Company's website.
- 08/10/2021
|
Cue Biopharma to Present Corporate Update at the Upcoming BTIG Virtual Biotechnology Conference
- CAMBRIDGE, Mass., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells directly within the patient's body, announced today that it will participate in a fireside chat at the BTIG Virtual Biotechnology Conference being held August 9-10 2021.
- 08/03/2021
|
Earnings Preview: Cue Biopharma, Inc. (CUE) Q2 Earnings Expected to Decline
- Cue Biopharma, Inc. (CUE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 07/30/2021
|
Cue Biopharma to Present at the Upcoming JMP Securities Life Sciences Conference
- CAMBRIDGE, Mass., June 14, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells directly within the patient's body, announced today that it will take part in a fireside chat at the JMP Securities Life Sciences Conference being held June 16-17, 2021.
- 06/14/2021
|
Cue Biopharma to Present at the 2021 Federation of Clinical Immunology Societies (FOCIS) Virtual Annual Meeting
- CAMBRIDGE, Mass., June 03, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells directly within the patient's body, announced today it will give a presentation at the 2021 Federation of Clinical Immunology Societies (FOCIS) Annual Meeting, which is being held virtually from June 8-11, 2021.
- 06/03/2021
|
Cue Biopharma, Inc. (CUE) CEO Daniel Passeri on Q1 2021 Results - Earnings Call Transcript
- Cue Biopharma, Inc. (CUE) CEO Daniel Passeri on Q1 2021 Results - Earnings Call Transcript
- 05/17/2021
|
Strength Seen in Cue Biopharma, Inc. (CUE): Can Its 27.7% Jump Turn into More Strength?
- Cue Biopharma, Inc. (CUE) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
- 05/11/2021
|
Cue Biopharma's Stock Shoots Up After CUE-101 Shows Promise In Early-Stage Head & Neck Cancer Study
- Cue Biopharma Inc (NASDAQ: CUE) has announced interim clinical data from its ongoing Phase 1a/1b monotherapy study of CUE-101 as second-line treatment for patients with human papilloma virus-positive recurrent/metastatic head and neck squamous cell carcinoma (HPV+ R/M HNSCC). Interim analysis highlights include: Confirmed partial response (PR) in one patient and stable disease (SD) in five patients, providing early signs of potential single-agent activity of CUE-101.
- 05/10/2021
|
Market Update: The 10 Most Volatile Stocks Today
- Joins us as we take a look at the most volatile stocks for Monday as many shares see their prices fluctuate during the day. The post Market Update: The 10 Most Volatile Stocks Today appeared first on InvestorPlace.
- 05/10/2021
|
Cue Biopharma to Host Business Update Call and Webcast
- CAMBRIDGE, Mass., May 10, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells directly within the patient's body, announced today it will host a conference call and webcast to provide a business update on Monday, May 17, 2021 at 4:30 p.m. EDT. Live and archived versions of the event can be accessed via the Company's website.
- 05/10/2021
|
CUE Stock: Over 10% Increase Pre-Market Explanation
- The stock price of Cue Biopharma Inc (NASDAQ: CUE) increased by over 10% pre-market. This is why it happened.
- 05/10/2021
|
Cue Biopharma, Inc. (CUE) CEO Daniel Passeri on Q4 2020 Results - Earnings Call Transcript
- Cue Biopharma, Inc. (CUE) CEO Daniel Passeri on Q4 2020 Results - Earnings Call Transcript
- 03/16/2021
|
Cue Biopharma Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Business Highlights
- CAMBRIDGE, Mass., March 16, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells directly within the patient's body, provided a business update for the fourth quarter and full year 2020.
- 03/16/2021
|
Cue Biopharma to Host Business Update Call and Webcast
- CAMBRIDGE, Mass., March 09, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells directly within the patient's body, announced today it will host a conference call and webcast to provide a business update on Tuesday, March 16, 2021 at 4:30 p.m. EDT. Live and archived versions of the event can be accessed via the Company's website.
- 03/09/2021
|
Cue Biopharma to Present at the Cowen 41st Annual Health Care Conference
- CAMBRIDGE, Mass., March 01, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells within the patient's body, announced today that it will present at the Cowen 41st Annual Health Care Conference being held virtually from March 1-4, 2021.
- 03/01/2021
|
Cue Biopharma Announces Appointment of Matteo Levisetti, M.D. as Senior Vice President of Clinical Development
- Appointment to strengthen clinical development capabilities with a strategic and visionary immunotherapy leader as Cue Biopharma advances its pipeline of drug development programs
- 02/17/2021
|
NexImmune Proposes Terms For $75 Million IPO
- NexImmune Proposes Terms For $75 Million IPO
- 02/08/2021
|
7 Stocks With Insider Buying This Week Worth A Look
- Insider buying is often a profitable signal for bulls. Insiders only buy for one reason: they believe their company's stock is going higher.
- 01/29/2021
|
Cue Biopharma: CUE-101's Phase 1 Promising Progress, 1 New IND Expected, Funding Until Q2 2022
- Cue Biopharma is a clinical-stage biopharmaceutical company developing novel injectables that modulate targeted T-cells. Cue Biopharma has expanded its pipeline to include 7 therapeutics with 1 undergoing clinical trials (CUE-101). CUE-101 is Cue's lead therapeutic halfway through Phase 1 and targeting HPV-related cancers.
- 01/07/2021
|
Cue Biopharma to Present at the Piper Sandler 32nd Annual Healthcare Conference
- CAMBRIDGE, Mass., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells within the patient's body, announced today that it participated in a pre-recorded fireside chat as part of the Piper Sandler 32nd Annual Virtual Healthcare Conference, being held on December 1-3, 2020.
- 11/23/2020
|
Cue Biopharma Extends Research Collaboration for the Development of Immuno-STAT Biologics for the Treatment of Defined Autoimmune Diseases with Merck
- CAMBRIDGE, Mass., Nov. 19, 2020 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the patient's body, announced today that the company has extended the term of the research program under its existing 2017 research collaboration and license agreement with Merck toward developing a clinical candidate for the treatment of type 1 diabetes and an additional undisclosed autoimmune disease.
- 11/19/2020
|
Cue Biopharma Reports Third Quarter 2020 Results and CUE-101 Phase 1 Dose Escalation Trial Updates
- CAMBRIDGE, Mass., Nov. 17, 2020 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells within the patient's body, provided a business update for the third quarter of 2020.
- 11/17/2020
|
Cue Biopharma to Present at Upcoming Investor Conferences in November 2020
- CAMBRIDGE, Mass., Nov. 11, 2020 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the patient's body, announced today that it will present at the Stifel Virtual Healthcare Conference on Wednesday, November 18, 2020 and the Jefferies Virtual London Healthcare Conference on Thursday, November 19, 2020.
- 11/11/2020
|
Cue Biopharma to Host Business Update Call and Webcast
- CAMBRIDGE, Mass., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the patient's body, announced today it will host a conference call and webcast to provide a business update on Tuesday, November 17, 2020 at 4:30 p.m. EST. Live and archived versions of the event can be accessed via the Company's website.
- 11/10/2020
|
Cue Biopharma Announces Presentations Highlighting Clinical Progress of CUE-101, Pipeline Progress of CUE-100 Series Immuno-STATs and Immuno-STAT Data for Infectious Disease Applications at the Society for Immunotherapy of Cancer's (SITC) 35th Anniversary Annual Meeting
- CAMBRIDGE, Mass., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the patient's body, announced today three poster presentations highlighting the Company's clinical and pipeline progress at the Society for Immunotherapy of Cancer's 35th Anniversary Annual Meeting (SITC 2020). The posters include a clinical update on CUE-101, the lead drug candidate from the IL-2 based CUE-100 series, and data supporting the potential of the Immuno-STAT™ (Selective Targeting and Alteration of T cells) platform to selectively engage and modulate targeted T cells within the body in a manner that can address a broad range of indications.
- 11/09/2020
|
HHS invests $480 million in Cue Health to boost manufacturing of rapid coronavirus test
- "Cue's tests provide results in about 20 minutes with the kind of accuracy provided by lab tests that can take several days, adding to our dramatically expanding supply of rapid tests that can support safe reopening," HHS Secretary Alex Azar said.
- 10/13/2020
|
Fintech Machine Learning Leader Attunely Secures $9M in Funding
- Fintech Machine Learning Leader Attunely Secures $9M in Funding
- 09/24/2020
|
Cue Biopharma Announces Nature Methods Publication of Preclinical Data Showing Tumor Penetration and Antigen-Specific T Cell Engagement with Immuno-STAT Based Protein Scaffolds
- Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively
- 09/15/2020
|
Wall Street Breakfast: The Week Ahead
- Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify.
- 09/13/2020
|
Stocks To Watch: Apple, Snowflake, Pfizer And Moderna In Focus
- Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning.
- 09/12/2020
|
How To Predict Sales Growth
- I've found seven factors that correlate highly with future sales growth; this article explains each one.
- 09/08/2020
|
Cue Biopharma, Inc. (CUE) CEO Dan Passeri on Q2 2020 Results - Earnings Call Transcript
- Cue Biopharma, Inc. (NASDAQ:CUE) Q2 2020 Results Earnings Conference Call August 31, 2020, 04:30 PM ET Company Participants George Zavoico - Vice President, Investor Relations & Corporate Development Dan Passeri - President and Chief Executive Officer Anish Suri - Chief Scientific Officer Ken Pienta - Acting Chief Medical Officer Kerri-Ann Millar - VP of Finance and Principal Accounting and Finance Officer Conference Call Participants Stephen Willey - Stifel Madhu Kumar - Baird Thomas Shrader - BTIG Reni Benjamin - JMP Security Mark Breidenbach - Oppenheimer Presentation Operator Thank you for standing by.
- 09/01/2020
|
Wall Street Breakfast: The Week Ahead
- Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify.
- 08/30/2020
|
Stocks To Watch: Nvidia, Intel And Zoom Look To Dazzle
- Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning.
- 08/29/2020
|
DeFi fintech studio Framework Labs raises $8M seed round » CryptoNinjas
- Framework Labs, a fintech studio for the rapidly emerging “Decentralized Finance” or “DeFi” industry, has closed an $8 million seed round of financing led
- 08/27/2020
|
Cue Biopharma to Host Business Update Call and Webcast
- CAMBRIDGE, Mass., Aug. 17, 2020 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the body, announced today it will host a conference call and webcast to provide a business update on Monday, August 31, 2020 at 4:30 p.m. EDT. Live and archived versions of the event can be accessed via the Company’s website. Members of the Cue Biopharma executive management team will provide an update on the Company’s ongoing Phase 1 clinical trial of CUE-101 for the treatment of HPV16-driven recurrent/metastatic head and neck squamous cell carcinoma (HNSCC), technology platforms and pipeline progress, as well as updates on its strategic objectives and anticipated milestones.Monday, August 31 at 4:30 p.m. EDT Investors: International: Conference ID: Webcast:855-327-6837 631-891-4304 10010557 http://public.viavid.com/index.php?id=141034 About Cue Biopharma Cue Biopharma, a clinical-stage biopharmaceutical company, is engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the body to transform the treatment of cancer, infectious diseases and autoimmune diseases. The company’s proprietary Immuno-STAT™ (Selective Targeting and Alteration of T cells) platform is designed to harness the body’s intrinsic immune system without the need for ex vivo manipulation.Headquartered in Cambridge, Massachusetts, we are led by an experienced management team and independent Board of Directors with deep expertise in the design and clinical development of protein biologics, immunology and immuno-oncology treatments.For more information, visit www.cuebiopharma.com and follow us on Twitter https://twitter.com/CueBiopharma.Forward-Looking Statements This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be covered by the “safe harbor” created by those sections. Forward-looking statements, which are based on certain assumptions and describe our future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as “believe,” “potential,” “expect,” “may,” “will,” “should,” “would,” “could,” “seek,” “intend,” “plan,” “goal,” “project,” “estimate,” “anticipate,” “strategy,” “future,” “likely” or other comparable terms. All statements other than statements of historical facts included in this press release regarding our strategies, prospects, financial condition, operations, costs, plans and objectives are forward-looking statements. Examples of forward-looking statements include, among others, statements we make regarding anticipated results of our drug development efforts, including study results, our expectations regarding attractive therapeutic window potential, regulatory developments and expected future operating results. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, our limited operating history, limited cash and a history of losses; our ability to achieve profitability; potential setbacks in our research and development efforts including negative or inconclusive results from our preclinical studies; our ability to secure required U.S. Food and Drug Administration (“FDA”) or other governmental approvals for our product candidates and the breadth of any approved indication; adverse effects caused by public health pandemics, including COVID-19, including possible effects on our operations and clinical trials; negative or inconclusive results from our clinical studies or serious and unexpected drug-related side effects or other safety issues experienced by participants in our clinical trials; delays and changes in regulatory requirements, policy and guidelines including potential delays in submitting required regulatory applications to the FDA; our reliance on collaborators, contract research organizations, suppliers and other business partners; our ability to obtain adequate financing to fund our business operations in the future; and the other risks and uncertainties described in the Risk Factors and in Management's Discussion and Analysis of Financial Condition and Results of Operations sections of our most recently filed Annual Report on Form 10-K and any subsequently filed Quarterly Report(s) on Form 10-Q. Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.Investor Contact George B. Zavoico, Ph.D. VP, Investor Relations & Corporate Development Cue Biopharma, Inc. gzavoico@cuebio.comMedia Contact Alison Chen LifeSciCommunications achen@lifescicomms.com
- 08/17/2020
|
Cue Biopharma, Inc. (CUE) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
- Cue Biopharma, Inc. (CUE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 08/06/2020
|
Vident Investment Advisory LLC Acquires New Stake in Cue Biopharma Inc (NASDAQ:CUE)
- Vident Investment Advisory LLC bought a new position in Cue Biopharma Inc (NASDAQ:CUE) during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 52,900 shares of the company’s stock, valued at approximately $1,297,000. Vident Investment Advisory LLC owned about 0.19% of Cue Biopharma as of its most […]
- 08/03/2020
|
Morgan Stanley Has $556,000 Stock Position in Cue Biopharma Inc (NASDAQ:CUE)
- Morgan Stanley lessened its stake in Cue Biopharma Inc (NASDAQ:CUE) by 48.4% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 39,202 shares of the company’s stock after selling 36,826 shares during the quarter. Morgan Stanley’s holdings in Cue Biopharma were worth $556,000 […]
- 08/03/2020
|
Cue Biopharma Begins Dosing Cohort 5 in an Ongoing Phase 1 Monotherapy Trial of CUE-101 in HPV+ Recurrent/Metastatic Head and Neck Cancer
- * CUE-101 advances to cohort 5 following Safety Review Committee assessment of expanded cohort 4 * Cohort 5 is fully enrolled, with first patient having been dosed on July 20 * Additional patients to be enrolled in cohort 4 to further characterize pharmacodynamics and clinical activity in support of selecting a recommended Phase 2 doseCAMBRIDGE, Mass., July 28, 2020 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells within the body, announced today it has advanced CUE-101 into cohort 5 in its ongoing multicenter, open-label, dose escalation Phase 1 monotherapy trial in patients with human papilloma virus-positive recurrent/metastatic head and neck squamous cell carcinoma (HPV+ HNSCC) (NCT03978689).Patients in cohort 5 will receive 2 mg/kg of CUE-101, which is two times the CUE-101 dose of 1 mg/kg in cohort 4. The first patient in cohort 5 received their dose and has been monitored for the initial protocol safety period of seven days with no evidence of adverse reactions. The next two patients in cohort 5 have been identified and have been scheduled to receive their first dose of CUE-101.As previously noted in a press release dated June 15, 2020, three additional patients were enrolled in cohort 4 at the recommendation of the Safety Review Committee to further characterize immune activity and confirm safety after one of the first three patients in cohort 4 experienced a possible treatment-related dose limiting toxicity (DLT). That patient subsequently received the next planned dose of CUE-101 at the same 1.0 mg/kg dosage without an observed adverse event. As no serious (Grade 3 or higher) treatment-related adverse events were observed during a 21-day safety evaluation period for the three additional cohort 4 patients, Cue Biopharma received approval from the Safety Review Committee to initiate enrollment and treatment of patients in cohort 5.“We are pleased to have enrolled three more patients in cohort 4 and to rapidly initiate cohort 5. Our progress is due, in large part, to the continued enthusiasm and support of our leading investigators during this challenging and uncertain time of COVID-19,” said Ken Pienta, M.D., acting chief medical officer of Cue Biopharma. “In parallel to evaluating CUE-101 at the cohort 5 dose level, we have identified additional patients to be enrolled in a further expansion of up to nine patients in cohort 4, as permitted per protocol. This allows us to further enhance our understanding of the pharmacokinetics (PK), pharmacodynamics (PD), and clinical activity of CUE-101 at what we believe could be a clinically active dose.”To date, sixteen patients have been dosed in the Phase 1 trial. Apart from a patient in cohort 4 with a possible treatment-related Grade 3 DLT as mentioned above, there have been no other DLTs. Importantly, the Grade 3 DLT and all other reported adverse events have resolved without further complications. To date, there have been no patient discontinuations from the trial due to adverse events.About the CUE-100 Series The CUE-100 series consists of Fc-fusion biologics that incorporate peptide-MHC (pMHC) molecules along with rationally engineered IL-2 molecules. This singular biologic is anticipated to selectively target, activate and expand a robust repertoire of tumor-specific T cells directly in the patient. The binding affinity of IL-2 for its receptor has been deliberately attenuated to achieve preferential selective activation of tumor-specific effector T cells while reducing potential for effects on regulatory T cells (Tregs) or broad systemic activation, potentially mitigating the dose-limiting toxicities associated with current IL-2-based therapies.About Cue Biopharma Cue Biopharma, a clinical-stage biopharmaceutical company, is engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the body to transform the treatment of cancer, infectious diseases and autoimmune diseases. The company’s proprietary Immuno-STAT™ (Selective Targeting and Alteration of T cells) platform is designed to harness the body’s intrinsic immune system without the need for ex vivo manipulation.Headquartered in Cambridge, Massachusetts, we are led by an experienced management team and independent Board of Directors with deep expertise in the design and clinical development of protein biologics, immunology and immuno-oncology treatments.For more information, visit www.cuebiopharma.com and follow us on Twitter https://twitter.com/CueBiopharma.Forward-Looking Statements This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be covered by the “safe harbor” created by those sections. Forward-looking statements, which are based on certain assumptions and describe our future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as “believe,” “potential,” “expect,” “may,” “will,” “should,” “would,” “could,” “seek,” “intend,” “plan,” “goal,” “project,” “estimate,” “anticipate,” “strategy,” “future,” “likely” or other comparable terms. All statements other than statements of historical facts included in this press release regarding our strategies, prospects, financial condition, operations, costs, plans and objectives are forward-looking statements. Examples of forward-looking statements include, among others, statements we make regarding anticipated results of our drug development efforts, including study results, our expectations regarding attractive therapeutic window potential, regulatory developments and expected future operating results. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, our limited operating history, limited cash and a history of losses; our ability to achieve profitability; potential setbacks in our research and development efforts including negative or inconclusive results from our preclinical studies; our ability to secure required U.S. Food and Drug Administration (“FDA”) or other governmental approvals for our product candidates and the breadth of any approved indication; adverse effects caused by public health pandemics, including COVID-19, including possible effects on our operations and clinical trials; negative or inconclusive results from our clinical studies or serious and unexpected drug-related side effects or other safety issues experienced by participants in our clinical trials; delays and changes in regulatory requirements, policy and guidelines including potential delays in submitting required regulatory applications to the FDA; our reliance on collaborators, contract research organizations, suppliers and other business partners; our ability to obtain adequate financing to fund our business operations in the future; and the other risks and uncertainties described in the Risk Factors and in Management's Discussion and Analysis of Financial Condition and Results of Operations sections of our most recently filed Annual Report on Form 10-K and any subsequently filed Quarterly Report(s) on Form 10-Q. Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.Investor Contact Ashley R. Robinson LifeSci Advisors arr@lifesciadvisors.comMedia Contact Alison Chen LifeSci Communications achen@lifescicomms.com
- 07/28/2020
|
Third Federal Savings and Loan Association of Cleveland, MHC Members Approve Dividend Waiver
- At today’s special meeting of members of Third Federal Savings and Loan Association of Cleveland, MHC, the mutual holding company and 81% majority sha
- 07/14/2020
|
Cue Biopharma Announces PLOS One Publication Demonstrating the Generation and Evaluation of Novel Molecules with Directed Mutations within the B7 Superfamily
- - Novel insights into receptor binding events and interfaces have led to generation of selective molecules with unique biochemical and functional properties through an effort.
- 07/08/2020
|
Here's What Cue Biopharma, Inc.'s (NASDAQ:CUE) Shareholder Ownership Structure Looks Like
- Every investor in Cue Biopharma, Inc. (NASDAQ:CUE) should be aware of the most powerful shareholder groups. Large...
- 07/06/2020
|
Nuveen Asset Management LLC Sells 44,220 Shares of Cue Biopharma Inc (NASDAQ:CUE)
- Nuveen Asset Management LLC lessened its position in shares of Cue Biopharma Inc (NASDAQ:CUE) by 33.8% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 86,559 shares of the company’s stock after selling 44,220 shares during the period. Nuveen Asset Management LLC owned approximately 0.30% […]
- 07/06/2020
|
Hedge Funds Have Never Been This Bullish On Cue Biopharma, Inc. (CUE)
- Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings. The 13F filings show the hedge funds' and successful investors' positions as of the end of the first quarter. You can find articles about an individual hedge fund's trades on numerous financial […]
- 06/28/2020
|
Politics and Policy: Drug firms called to embrace concept of public goods
- AN experimental drug for Covid-19 has put the spotlight on barriers to treatment for millions of people on the basis of marketing decisions by pharmaceutical companies. Malaysia has been excluded from a list of 127 nations that can have access to a generic form of Remdesivir, which US drug maker Gilead Sciences is allowing five manufacturers of generics to produce and market to the countries on the list.
- 06/18/2020
|
From hockey poster boy to forlorn star
- Faizal Saari is still devastated over his exclusion from the “Speedy Tigers” in February, and the continuing criticism by the Malaysian Hockey Confederation (MHC).
- 06/17/2020
|
Cue Biopharma Provides Update on Ongoing Phase 1 Trial Evaluating CUE-101 in Recurrent/Metastatic Head and Neck Cancer
- Cue Biopharma, Inc. (CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells within the body, is providing an update on its Phase 1 trial of CUE-101 monotherapy as second-line or later therapy for patients with HPV+ recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC). As of June 15, 2020, the ongoing Phase 1, first-in-human, multicenter trial has enrolled 13 patients, with a majority of patients having received multiple cycles of therapy. Out of the 13 patients enrolled, there are six patients presently remaining on study for ongoing data generation.
- 06/15/2020
|
Cue Health raises $100M to validate at-home flu test
- Cue Health, a startup developing a connected testing device, closed a $100 million series C round. The company recently submitted its system to the FDA for emergency use authorization to be used for onsite Covid-19 testing.
- 06/10/2020
|
Cue Biopharma to Present Corporate Overview and Pipeline Progress at Jefferies Virtual Healthcare Conference
- Cue Biopharma, Inc. (CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the body, announced today it will present at the Jefferies Virtual Healthcare Conference 2020 on Thursday, June 4, 2020 at 9:00 a.m. EDT. Daniel Passeri, chief executive officer, will provide an overview of the Company’s Immuno-STAT™ (Selective Targeting and Alteration of T cells) and Neo-STAT™ platforms and an update on the on-going clinical trial for its lead drug candidate CUE-101, as well as pipeline progress and anticipated corporate development milestones. The presentation will also be archived for 30 days on the Company's website.
- 05/28/2020
|
The Daily Biotech Pulse: FDA Nod For Aquestive, Tetraphase M&A Plot Thickens, Amarin's Vascepa In COVID Fray
- Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs May 21)
ADC Therapeutics SA (NYSE:...
- 05/22/2020
|
Cue Biopharma, Inc. (CUE) Q1 2020 Earnings Call Transcript
- Greetings, and welcome to Cue Biopharma first-quarter 2020 earnings call. It is now my pleasure to introduce your host Ashley Robinson, investor relations. This is Ashley from LifeSci Advisors, and thank you for joining us on today's investor and analyst update call.
- 05/21/2020
|
The Daily Biotech Pulse: Mixed Filgotinib Readout For Gilead-Galapagos, Akorn To File For Chapter 11, D-Day For Aquestive
- Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech stocks that hit 52-week highs on May 20.)
ADC Therapeutics SA (...
- 05/21/2020
|
Cue Biopharma Reports First Quarter 2020 Results, Updates of CUE-101 Phase 1 Dose Escalation Study and Recent Business Highlights
- CAMBRIDGE, May 19, 2020 (GLOBE NEWSWIRE via COMTEX) -- Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel...
- 05/19/2020
|
Cue Biopharma Reports First Quarter 2020 Results, Updates of CUE-101 Phase 1 Dose Escalation Study and Recent Business Highlights
- CAMBRIDGE, Mass., May 19, 2020 -- Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively.
- 05/19/2020
|
Cue Biopharma to Present at AACR Virtual Annual Meeting
- Cue Biopharma, Inc. (CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the body, announced today a poster presentation featuring pre-clinical data on CUE-102/A02 and CUE-102/A24, the company’s second and third drug candidates from the CUE-100 series at the American Association for Cancer Research (AACR) Virtual Annual Meeting II. CUE-102 biologics are Immuno-STATs™ (Selective Targeting and Alteration of T cells) designed to selectively target and expand Wilms’ tumor 1 (WT1) specific T cells for the treatment of patients with solid and hematological cancers.
- 05/18/2020
|
Cue Biopharma Announces Strategic Research Collaboration with Dr. Michael Dustin and Oxford University
- Cue Biopharma, Inc. (CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the body, announced today it has entered into a research collaboration agreement with Dr. Michael Dustin and the University of Oxford to determine the molecular mechanisms underlying the activity of its IL-2 based CUE-100 series Immuno-STAT™ (Selective Targeting and Alteration of T cells) Biologics. “Cue Biopharma is pleased to enter into this strategic collaboration with Dr. Dustin and the University of Oxford,” said Saso Cemerski, senior director of immuno-oncology discovery and translational immunology at Cue Biopharma.
- 05/14/2020
|
Cue Biopharma to Host Business Update Call and Webcast
- Cue Biopharma, Inc. (CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the body, announced today it will host a conference call and webcast to provide a business update on Tuesday, May 19, 2020 at 4:30 p.m. EDT. Members of the Cue Biopharma executive management team will provide an update on the Company’s platform and pipeline progress, as well as updates on its strategic objectives and anticipated milestones. Cue Biopharma, a clinical-stage biopharmaceutical company, is engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the body to transform the treatment of cancer and autoimmune diseases.
- 05/12/2020
|
The Daily Biotech Pulse: NASH Disappointment For Genfit, Novavax Lands $384M CEPI Funding For Coronavirus Vaccine, GW Pharma Earnings
- Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs May 11)
Acceleron Pharma Inc (NASDAQ...
- 05/12/2020
|
Cue Biopharma, Inc.
(CUE) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
- Cue Biopharma, Inc. (CUE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 05/06/2020
|
The Daily Biotech Pulse: FDA Nod For GlaxoSmithKline, Hologic To Launch Coronavirus Test, Amarin's Strong Q1
- Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 29)• Arvinas Inc (NASDAQ: ARVN) • Biondvax Pharmaceuticals Ltd - ADR (NASDAQ: BVXV) • Bio-Rad Laboratories, Inc. Class A Common Stock(NYSE: BIO) • Capricor
- 04/30/2020
|
The Daily Biotech Pulse: FDA Nod For GlaxoSmithKline, Hologic To Launch Coronavirus Test, Amarin's Strong Q1
- Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs April 29)
• Arvinas Inc (NASDAQ...
- 04/30/2020
|
Dynamic New Players Gain Momentum In Digital, Data And Patient-Centric Space
- Not only vaccines-oriented pharma, teleworking, or food delivery companies draw the attention of investors. By the same token, COVID-19 is not the only virus on
- 04/28/2020
|
Zacks.com featured highlights include: ThermoGenesis, 21Vianet, Livongo Health, Cue Biopharma and Sharps Compliance
- Zacks.com featured highlights include: ThermoGenesis, 21Vianet, Livongo Health, Cue Biopharma and Sharps Compliance
- 04/27/2020
|
Zacks.com featured highlights include: ThermoGenesis, 21Vianet, Livongo Health, Cue Biopharma and Sharps Compliance
- Zacks.com featured highlights include: ThermoGenesis, 21Vianet, Livongo Health, Cue Biopharma and Sharps Compliance
- 04/27/2020
|
Cue Biopharma (NASDAQ:CUE) Upgraded by BidaskClub to "Strong-Buy"
- Cue Biopharma (NASDAQ:CUE) was upgraded by equities research analysts at BidaskClub from a “buy” rating to a “strong-buy” rating in a research note issued to investors on Saturday, BidAskClub reports. A number of other equities research analysts have also recently issued reports on CUE. Zacks Investment Research raised shares of Cue Biopharma from a “hold” […]
- 04/25/2020
|
The Zacks Analyst Blog Highlights: Cue Biopharma, PJT Partners, Avenue Therapeutics, SpartanNash and Gaia
- The Zacks Analyst Blog Highlights: Cue Biopharma, PJT Partners, Avenue Therapeutics, SpartanNash and Gaia
- 04/24/2020
|
The Zacks Analyst Blog Highlights: Cue Biopharma, PJT Partners, Avenue Therapeutics, SpartanNash and Gaia
- The Zacks Analyst Blog Highlights: Cue Biopharma, PJT Partners, Avenue Therapeutics, SpartanNash and Gaia
- 04/24/2020
|
3 Monster Growth Stocks Gearing up for Gains
- Just when it looked like time to throw in the towel, the market pulled through and delivered a win. Stabilizing crude oil prices, a few better-than-expected earnings reports as well as the possibility of a fresh fiscal stimulus package all helped inspire confidence among investors.While April's rally
- 04/24/2020
|
The Daily Biotech Pulse: FDA Approves Sanofi's Meningococcal Vaccine, Pluristem Secures $54M In Funding For COVID-19 Treatment, Oric Pharma Prices IPO
- Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech stocks hitting 52-week highs April 23.) * Arcturus Therapeutics Ltd (NASDAQ: ARCT) * Chembio Diagnostics Inc (NASDAQ: CEMI) * Cue Biopharma Inc (NASDAQ: CUE) * Eli Lilly And Co (NYSE: LLY
- 04/24/2020
|
5 Stocks With Recent Price Strength to Tap Market Rally
- Investors target stocks that are witnessing a bullish run. Actually, stocks seeing price strength have a high chance of carrying the momentum forward.
- 04/24/2020
|
Stocks That Hit 52-Week Highs On Thursday
- During Thursday's morning trading, these companies set new 52-week highs.Noteworthy Points: * Johnson & Johnson (NYSE: JNJ) was the largest company by market cap to set a new 52-week high. * The smallest company when looking at market cap to set a new 52-week high was LightPath Technologies (NASDAQ
- 04/23/2020
|
Stocks Recover About 2% After Oil Stabilizes
- Stocks Recover About 2% After Oil Stabilizes
- 04/23/2020
|
The Daily Biotech Pulse: FDA Nod For Immunomedics, Lilly's Solid Q1 Beat, Predictive Oncology Restructures Debt
- Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech stocks htitting 52-week highs April 22.) * Dr.Reddy's Laboratories Ltd (NYSE: RDY) * Johnson & Johnson (NYSE: JNJ) (reacted to a sell-side upgrade) * Cue Biopharma Inc (NASDAQ: CUE)
- 04/23/2020
|
5 Top Small-Cap Stocks Braving Coronavirus Bloodbath
- A handful of small-cap stocks have skyrocketed defying the coronavirus-induced market mayhem and extreme volatility.
- 04/23/2020
|
5 Top Small-Cap Stocks Braving Coronavirus Bloodbath
- A handful of small-cap stocks have skyrocketed defying the coronavirus-induced market mayhem and extreme volatility.
- 04/23/2020
|
Cue Biopharma price target raised to $25 from $21 at Stifel CUE
- Cue Biopharma price target raised to $25 from $21 at Stifel Stifel CUE
- 04/21/2020
|
Cue Biopharma, Merck enter into clinical trial collaboration agreement CUE;MRK
- Cue Biopharma, Merck enter into clinical trial collaboration agreement CUE MRK
- 04/20/2020
|
Cue BiopharmaAnnounces Clinical Trial Collaboration Agreement with Merck to Evaluate CUE-101 in Combination with KEYTRUDA (pembrolizumab) as First-line Treatment For HPV+ Recurrent/Metastatic Head and Neck Cancer
- Cue Biopharma, Inc. (CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the body, announced today it has entered into a clinical collaboration agreement with Merck (known as MSD outside the United
- 04/20/2020
|
Cronos Financials 'Restatement', And Other News: The Good, Bad And Ugly Of Biopharma
- Cronos said it will need to restate parts of its financial statements. Biohaven's migraine drug gets fast tracked. Cue biopharma's earnings.
- 03/20/2020
|
Cue Biopharma Reports Fourth Quarter and Full Year 2019 Financial Results and Recent Business Highlights
- Extended cash runway with $33.3 million from at-the-market equity offerings in Q4’19Focused and effective execution of clinical development of CUE-101 as a Phase 1 monotherapy.
- 03/17/2020
|
The Week Ahead In Biotech: COVID-19 Updates, Tapering Earnings Flow, Eton's Seizure Drug Review
- The biopharma space bled along with the rest of the market and COVID-19 levered biotechs weren't spared either.Biogen Inc (NASDAQ: BIIB) was in the news for all wrong reasons, as an employee conference held by the company in Boston from Feb. 24 to 27 was blamed for 77 of the 95 COVID-19 cases reported
- 03/15/2020
|
The Week Ahead In Biotech: COVID-19 Updates, Tapering Earnings Flow, Eton's Seizure Drug Review
- The biopharma space bled along with the rest of the market and COVID-19 levered biotechs weren't spared either.
Biogen Inc (NASDAQ: BIIB) was in the news for all wrong...
- 03/15/2020
|
Stocks To Watch: 0% To The Rescue?
- Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive th
- 03/14/2020
|
Framework Ventures Invests $400,000 in Futureswap, a Decentralized Futures Exchange, and $500,000 in Commonwealth Labs
- Framework Ventures invests $400,000 in Futureswap, a decentralized futures exchange, and $500,000 in Commonwealth Labs.
- 03/12/2020
|
Should You Buy Cue Biopharma (CUE) Ahead of Earnings
- Cue Biopharma (CUE) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
- 03/11/2020
|
The Cue Biopharma (NASDAQ:CUE) Share Price Has Gained 191%, So Why Not Pay It Some Attention?
- The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But if you pick the right...
- 03/09/2020
|
The Daily Biotech Pulse: Breakthrough Device Designation For Neuronetics, AbbVie Receives European Label Expansion, AstraZeneca Flunks Late-Stage Study
- Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech stocks that hit hit 52-week highs March 5.) * Arcus Biosciences Inc (NYSE: RCUS) * Arcturus Therapeutics Ltd (NASDAQ: ARCT) * BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) * Centogene NV
- 03/06/2020
|
The Daily Biotech Pulse: Trevana Pain Drug Resubmission Accepted For Review, Can-Fite To Explore Treatment For COVID-19
- Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 4) * 89bio Inc (NASDAQ: ETNB) * Arcus Biosciences Inc (NYSE: RCUS) * Arcturus Therapeutics Ltd (NASDAQ: ARCT)(announced a partnership with Duke-NUS
- 03/05/2020
|
Cue Biopharma to Present at Upcoming Investor Conferences in March 2020
- Cue Biopharma, Inc. (CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the body, announced today it will present at the Cowen & Co. 40th Annual Health Care Conference on Monday, March 2, 2020 in Boston, Massachusetts and the 30th Annual Oppenheimer Healthcare Conference on Wednesday, March 18, 2020 in New York. A live and archived version of the webcast will be available at http://wsw.com/webcast/cowen57/cue/.
- 02/26/2020
|
The Daily Biotech Pulse: FDA Approves Baudax Bio's Non-Opioid Pain Drug, Aerie Rallies On Q4 Results, D-Day For Esperion
- Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs on Feb. 20.) Akebia Therapeutics Inc (NASDAQ: AKBA ) Aptose Biosciences ...
- 02/21/2020
|
The Daily Biotech Pulse: Heron Pain Drug Review Extended, Disappointment For Teva In Tourette Syndrome Study
- Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 19) Adverum Biotechnologies Inc (NASDAQ: ADVM ) Akebia ...
- 02/20/2020
|
Cue Biopharma’s Therapeutic Immuno-STAT Platform to be Featured in Merck Presentation at Antigen-Specific Immune Tolerance Drug Development Summit
- Cue Biopharma, Inc. (CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the body, announced today that the company’s therapeutic Immuno-STAT™ (Selective Targeting and Alteration of T cells) platform is scheduled to be featured in a Merck presentation at the Antigen-Specific Immune Tolerance Drug Development Summit taking place on Feb. 25-27, 2020 at the Colonnade Hotel in Boston, Massachusetts. Cue entered into a strategic research collaboration and license agreement with Merck in November 2017 to develop biologics for the treatment of selected autoimmune diseases.
- 02/19/2020
|
Zacks.com featured highlights include: Farmers National, Independent Bank, First Financial Bankshares, HarborOne and Cue Biopharma
- Zacks.com featured highlights include: Farmers National, Independent Bank, First Financial Bankshares, HarborOne and Cue Biopharma
- 02/14/2020
|
Zacks.com featured highlights include: Farmers National, Independent Bank, First Financial Bankshares, HarborOne and Cue Biopharma
- Zacks.com featured highlights include: Farmers National, Independent Bank, First Financial Bankshares, HarborOne and Cue Biopharma
- 02/14/2020
|
5 Stocks to Make the Most of New Analyst Coverage
- Increased analyst coverage over the last few weeks might lead to solid price appreciation for these stocks.
- 02/13/2020
|
The Daily Biotech Pulse: J&J Intensifies Efforts On COVID-19 Cure, Adamas Reports Positive, Long-Term Gocovri Data
- Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 11) AbbVie Inc (NYSE: ABBV ) Acceleron Pharma Inc (NASDAQ: ...
- 02/12/2020
|
Cue Biopharma to Present at the Biomarkers Series UK
- Cue Biopharma, Inc. (CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the body, announced today Dr. Mary Simcox, vice president of translational biology and early development, will give a presentation highlighting the strategy and tactical details for testing CUE-101, the company’s lead biologic drug candidate, in a first-in-human Phase 1 trial (NCT03978689) at the Biomarkers Series UK taking place on Feb. 18-20, 2020 at the Manchester Central Convention Complex.
- 02/12/2020
|
The Daily Biotech Pulse: LogicBio Slapped With Clinical Hold, Agile Inks Debt Deal Ahead of Twirla Approval, Gilead Builds Stake In Sierra Oncology
- Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 10) AbbVie Inc (NYSE: ABBV ) Allergan plc (NYSE: AGN ) ...
- 02/11/2020
|
BTIG: New Data Could Propel These 3 Biotech Stocks Higher in 2020
- For those who like patterns, biotech names’ growth stories tend to look remarkably similar. These stocks are less reliant on earnings reports and more on a few select markers which can decide what direction they will take in the near-term. A favorable outcome from a regulatory committee or promising data from a clinical trial can send the stock soaring. Conversely, rejection or disappointing readouts can send the company’s share price tumbling down. While they present possible mercurial upside, these tickers aren’t for the faint of heart because although the patterns usually play out, the direction they might take is very hard to predict.So, how should investors choose which biotechs to invest in? There are different strategies, of course, but one trusted way is to listen to the experts. Investment bank BTIG is a well-known name on the Street, housing several top analysts. The company has identified three companies in the sector that will present new data over the coming months, and BTIG analysts think positive results can propel each of them forward.Using the Stock Comparison tool from TipRanks, a company that tracks and measures the performance of analysts, we were able to zero in on their choices and find out why the firm finds them so compelling. Let’s get familiar with the data at hand. Sarepta Therapeutics (SRPT)Let’s start off with a good example of the impact regulatory forces can have on a stock. Sarepta Therapeutics made headlines towards the end of 2019, when the FDA approved Vyondys 53, the company’s treatment for Duchenne muscular dystrophy (DMD) patients with exon 53 mutations. The approval came as a surprise as only a few months earlier, Sarepta received the dreaded CRL (complete response letter) from the FDA following its original submission. As is de rigueur in the sector, Sarepta stock responded to the announcement by soaring over 30% in a day.In addition to the recently approved drug, the genetic disorder-focused biotech has a robust pipeline, with gene therapy programs in DMD and LGMD (Limb Girdle Muscular Dystrophy). BTIG’s Tim Chiang believes the company is steadily progressing with these key programs.The analyst said, “We believe SRPT is making progress on the gene therapy manufacturing front, and has achieved yields sufficient to begin study 301 (which we think could enroll up to a hundred or more patients). We believe SRPT plans to provide an interim look at data from this study in ~15 patients dosed (evaluating expression levels at ~3 months post dosing). In LGMD2E, SRPT has dosed two patients in the higher dose cohort, with a third patient to be dosed shortly. We expect a data read out from this high dose arm in early 2Q.”Chiang expects that US gene therapy sales in the DMD market will reach a peak in 2024, with the figure landing at roughly $2 billion. There are three companies currently in the race to develop gene therapies for the treatment of DMD; Sarepta, according to the analyst, is leading the way and could be the first to enter the US market with its gene therapy for DMD in the second half of 2021.Chiang added, “We think one of the key differences among the 3 micro-dystrophin gene therapy programs in the clinic are that both Solid Biosciences (SLDB, Neutral) and Pfizer have studies where ascending dose cohorts are being utilized. In contrast, Sarepta’s study incorporates just one dose (2E14 vg/kg).”So, what does this mean? It means Chiang kept his Buy rating on Sarepta, along with a price target of $190. Should the target be met, investors stand to see a handsome 64% gain over the next year. (To watch Chiang’s track record, click here)The Street, too, is bullish on the DMD fighter. A Strong Buy consensus rating breaks down into 18 Buys and a single Hold. The average price target comes in at $204.33 and indicates potential upside of 76%. (See Sarepta stock analysis on TipRanks) IMV Inc. (IMV)IMV’s market performance in 2019 was a disappointing affair; The stock lost 39% of its value along the way. By contrast, 2020’s performance so far has been the exact opposite - and some. The stock is up by 58% year-to-date. According to BTIG’s Thomas Shrader, there is more to come, too.The cancer fighter’s lead candidate is DPX-Survivac, which targets the surviving TAA (tumor associated antigen) that is overexpressed in more than 20 different types of cancers. Clinical data so far has been promising, with long disease-free intervals in the ovarian cancer (OC) adjuvant setting and compelling treatment response rates in both OC and DLBCL (diffuse large B-cell lymphoma). Important DPX-Survivac data is expected this quarter which Shrader notes “could greatly de-risk the current programs and potentially demonstrate the utility of the low-COGS DPX platform to deliver many other TAAs and neoantigens.”The 5-star analyst added, “The drug has shown robust and prolonged CD8 TCell responses in the adjuvant setting and a Phase 1b/2 trial has shown a 100% DCR and 60% ORR in the subgroup of patients with non-bulky disease (tumor burden < 5 cm) most of which are platinum-resistant (few treatment options). The company expects to provide topline Phase 2 monotherapy data in mid-February 2020 that we expect to be an important catalyst for the story.”Ahead of this upcoming data readout, Shrader is siding with the bulls. The analyst initiated coverage of IMV with a Buy rating along with an $8 price target. The implication? Further gains in the shape of 75% over the next 12 months. (To watch Shrader’s track record, click here)The Street agrees. A total of 6 Buys add up to a unanimous Strong Buy consensus rating. With an average price target of $9.31, the analysts see potential upside of 104% for IMV over the coming 12 months. (See IMV stock analysis on TipRanks) Cue Biopharma Inc. (CUE)A fellow company taking the fight to cancer is Cue Biopharma. In 2019, Cue’s exceptional performance beat the market considerably. The stock added an astounding 238% to its share price throughout the year. Following such a surge, though, is this the right time to get in on this high-flying biotech?Yes, it is, according to BTIG’s Thomas Shrader. In fact, the 5-star analyst just recently initiated coverage of Cue with an emphatic Buy rating. The thumbs up comes with a price target of $26, indicating Shrader believes an additional 71% will be added to Cue’s share price over the next 12 months.So, what’s all the fuss about, then? A cure for cancer is one of modern medicine’s most coveted prizes. Cue is working on an immunotherapy platform which will assist immune systems by recognizing solid tumor cells and repeatedly attacking them until they stop working.The company’s lead candidate is CUE-101, which was developed for patients with head and neck cancer driven by human papillomavirus (HPV). Topline results from a Phase 1 trial are expected later this year, and so far, results have been promising.Shrader said, “Data to date is preclinical but the lead programs termed CUE-101 has exploited well defined subunits and demonstrated tumor antigen-specific T-cells responses without the accompanying systemic immune toxicities that characterize many competing approaches… Preclinical data confirm both robust T-Cell responses and an attractive safety profile setting the stage for clinical studies. These studies have stated (first dosing September 2019) and, based on the preclinical safety profile, will begin with doses that could be efficacious. Clinical data validating the overall approach are expected around 3Q20 and, if promising, a significant pipeline in additional applications should be de-risked.”Currently, the rest of the Street remains rather quiet on Cue, with only one other analyst chipping in with a take on the biotech’s prospects. The additional Buy recommendation means Cue receives a Moderate Buy consensus rating. The average price target comes in at $24 and implies upside potential of 58%. (See Cue Biopharma stock analysis on TipRanks)
- 02/03/2020
|
Zacks.com featured highlights include: Independent Bank, HarborOne, Horizon Technology Finance and Cue Biopharma
- Zacks.com featured highlights include: Independent Bank, HarborOne, Horizon Technology Finance and Cue Biopharma
- 01/30/2020
|
4 Stocks in Focus as New Analysts Show Interest
- Increased analyst coverage over the last few weeks might lead to solid price appreciation for these stocks.
- 01/29/2020
|
4 Stocks in Focus as New Analysts Show Interest
- Increased analyst coverage over the last few weeks might lead to solid price appreciation for these stocks.
- 01/29/2020
|
BMO likes Seattle Genetics in premarket analyst action
- Acadia Healthcare (NASDAQ:ACHC) resumed with Equal Weight rating and $36 (11% upside) price target at Stephens.Applied Genetics Technologies (NASDAQ:AGTC) initiated with Buy rating and $25 (218% upsid
- 01/28/2020
|
Cue Biopharma Announces Publication in Clinical Cancer Research of Preclinical and Translational Data Supporting the Therapeutic Potential of CUE-101 in HPV16-Related Malignancies
- Cue Biopharma, Inc. (CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the body, announced today the publication of research demonstrating the ability of its lead biologic candidate CUE-101 to activate tumor antigen specific antitumor immunity in the peer-reviewed medical journal Clinical Cancer Research, a journal of the American Association for Cancer Research. In addition, mCUE-101 administered as a combination therapy with anti-PD-1 checkpoint inhibition further enhanced anti-tumor efficacy.
- 01/21/2020
|
Alnylam Provides Preliminary Q4 Sales for Onpattro & Givlaari
- Alnylam (ALNY) announces preliminary results for the fourth quarter and 2019 and provides other updates.
- 01/13/2020
|
Active Participants and Digital Assets: The SEC Coins a New Term
- Click HERE to find out ⭐ Active Participants and Digital Assets: The SEC Coins a New Term. | Crowdfund Insider: Global Fintech News, including Crowdfunding, Blockchain and more.
- 08/05/2019
|
